Mytos Launches Automated CDMO Offering

Mytos, a biotechnology company automating cell manufacturing, has launched an automated contract development and manufacturing organization (CDMO) offering designed to offer scalable, affordable manufacturing of stem cell-derived therapies.

The first facility, housed within the Cell and Gene Therapy Catapult’s (CGT Catapult) Stevenage Manufacturing Innovation Centre, is targeting clinical readiness by September 2026.

Powered by Mytos’ iDEM automation technology, Mytos’ team at the site aims to be able to deliver up to 1,500 autologous doses or 25,000 allogeneic doses annually, with additional cleanroom space available to further multiply capacity. The iDEM technology lowers the cost per dose, accelerates tech transfer by using the same flask format as manual culture, and gives developers immediate access to GMP capacity without the infrastructure costs or delays of traditional outsourcing.

“Regenerative medicine has extraordinary potential, but the cost and scalability of manual manufacture are barriers to reaching patients at scale,” said Ali Afshar, Ph.D., CEO and Co-Founder, Mytos. “With our automated iDEM-powered manufacturing sites, we’re addressing that challenge head-on. CGT Catapult’s expertise and status as a global cell and gene therapy innovation hub make this the ideal place to launch our first site and set a new standard for scaling regenerative medicines worldwide.”

This is the first of several planned global sites aimed at building the manufacturing backbone needed to bring regenerative medicines to millions of patients worldwide.